Harwood Feffer LLP Announces Investigation of Vical Incorporated

NEW YORK, Nov. 6, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Vical Incorporated ("Vical" or the "Company") (NASDAQ: VICL), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

Since approximately February 2012, Vical made repeated positive statements regarding the potential success of its immunotherapy vaccine for cancer, Allovectin.  The Company's positive statements included representations about the design and results of Allovectin's Phase 3 trial, efficacy, and likelihood of FDA approval.

On August 12, 2013, Vical disclosed that the Allovectin Phase 3 trial had shown no improvement over chemotherapy and that the Allovectin program would be terminated.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Vical shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400 
                           (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE Harwood Feffer LLP